Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 445

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 445
---
 The proprietary technology developed at the Company is based on quantitative analysis of circulating organ -enrichedmicroRNAs in plasma. Short -termobjectives of the Company include the development of Lab -Developedtests (LDTs) under CLIA guidelines based on the identified miRNA signatures. The tests will be used for screening, patient stratification, as well as disease and treatment monitoring. The Company was incorporated in Delaware on June 16, 2014 and primarily operates through its wholly -ownedsubsidiary, DiamiR, LLC, which was incorporated as a limited liability company in Delaware on September 17, 2009. In October 2014, the Company entered into a Share Exchange Agreement with DiamiR, LLC, pursuant to which the Company acquired 100% of the issued and outstanding units of DiamiR, LLC in exchange for 4,282,000shares (100%) of the Company’s common stock (the “Share Exchange”), and DiamiR, LLC became a wholly -ownedsubsidiary of the Company. The Share Exchange was recognized as a combination of entities under common control as both DiamiR, LLC and the Company have been controlled before and after the transaction by the same shareholders. The Company’s patent portfolio includes United States patents, issued between 2014 and 2021 and set to expire between 2030 and 2037, and certain foreign counterparts, in seven patent families. NOTE 2 — BASIS OF PRESENTATION The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. The Company currently operates in one business segment focusing on the development and commercialization of methods for the early detection and monitoring of neurodegenerative diseases. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer, who comprehensively manages the entire business. The Company does not currently operate any separate lines of business or separate business entities. Going Concern The Company has a limited operating history and has incurred a net loss of $614,405 and $1,318,431 for the years ended May 31, 2024 and 2023, respectively, and had net cash used in operating activities of $308,914 for the year ended May 31, 2024. Since the inception of the Company in September